BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51:1675-1682. [PMID: 20186844 DOI: 10.1002/hep.23500] [Cited by in Crossref: 271] [Cited by in F6Publishing: 216] [Article Influence: 22.6] [Reference Citation Analysis]
Number Citing Articles
1 Huang Y, Joseph J, de Boer WB, Cheng W, Adams LA, MacQuillan G, Garas G, Raftopoulos S, Jeffrey GP. Long-term Liver-related Outcomes of Patients With Chronic Liver Diseases in Australia. Clin Gastroenterol Hepatol 2020;18:496-504.e3. [PMID: 31319186 DOI: 10.1016/j.cgh.2019.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Hudson M, Radwan A, Di Maggio P, Cipelli R, Ryder SD, Dillon JF, Cash WJ, Przemioslo RT, Wright M, Shawcross DL, Jalan R, Saksena S, Allison M, Richardson P, Farrington E, Aspinall RJ. The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). Frontline Gastroenterol 2017;8:243-51. [PMID: 29067149 DOI: 10.1136/flgastro-2016-100792] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
3 Hajifathalian K, Humberson A, Hanouneh MA, Barnes DS, Arora Z, Zein NN, Eghtesad B, Kelly D, Hanouneh IA. Ohio solid organ transplantation consortium criteria for liver transplantation in patients with alcoholic liver disease. World J Hepatol 2016; 8(27): 1149-1154 [PMID: 27721920 DOI: 10.4254/wjh.v8.i27.1149] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Buchanan R, Sinclair JMA. Alcohol use disorder and the liver. Addiction 2021;116:1270-8. [PMID: 32710592 DOI: 10.1111/add.15204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Pateria P, de Boer B, MacQuillan G. Liver abnormalities in drug and substance abusers. Best Pract Res Clin Gastroenterol. 2013;27:577-596. [PMID: 24090944 DOI: 10.1016/j.bpg.2013.08.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
6 Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715-735. [PMID: 25042402 DOI: 10.1002/hep.27210] [Cited by in Crossref: 879] [Cited by in F6Publishing: 680] [Article Influence: 109.9] [Reference Citation Analysis]
7 Bernal W, Jalan R, Quaglia A, Simpson K, Wendon J, Burroughs A. Acute-on-chronic liver failure. Lancet. 2015;386:1576-1587. [PMID: 26423181 DOI: 10.1016/s0140-6736(15)00309-8] [Cited by in Crossref: 153] [Cited by in F6Publishing: 59] [Article Influence: 21.9] [Reference Citation Analysis]
8 Asrani SK, Simonetto DA, Kamath PS. Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol 2015;13:2128-39. [PMID: 26188138 DOI: 10.1016/j.cgh.2015.07.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
9 Greinert R, Zipprich A, Simón-Talero M, Stangl F, Ludwig C, Wienke A, Praktiknjo M, Höhne K, Trebicka J, Genescà J, Ripoll C. Covert hepatic encephalopathy and spontaneous portosystemic shunts increase the risk of developing overt hepatic encephalopathy. Liver Int 2020;40:3093-102. [PMID: 32890428 DOI: 10.1111/liv.14660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ott P. What is the Value of Country-Based Surveillance Programmes? In: Williams R, Taylor-robinson SD, editors. Clinical Dilemmas in Primary Liver Cancer. Oxford: Wiley-Blackwell; 2011. pp. 97-104. [DOI: 10.1002/9781119962205.ch14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Ratib S, Fleming KM, Crooks CJ, Aithal GP, West J. 1 and 5 year survival estimates for people with cirrhosis of the liver in England, 1998-2009: a large population study. J Hepatol. 2014;60:282-289. [PMID: 24128415 DOI: 10.1016/j.jhep.2013.09.027] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 8.4] [Reference Citation Analysis]
12 Majc D, Tepes B. The Impact of Outpatient Clinical Care on the Survival and Hospitalisation Rate in Patients with Alcoholic Liver Cirrhosis. Radiol Oncol 2018;52:75-82. [PMID: 29520208 DOI: 10.1515/raon-2017-0056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Olafsson S, Rögnvaldsson S, Bergmann OM, Jonasson JG, Benitez Hernandez U, Björnsson ES. A nationwide population-based prospective study of cirrhosis in Iceland. JHEP Rep 2021;3:100282. [PMID: 34041467 DOI: 10.1016/j.jhepr.2021.100282] [Reference Citation Analysis]
14 Zacharias HD, Zacharias AP, Gluud LL, Morgan MY. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. Cochrane Database Syst Rev 2019;6:CD012334. [PMID: 31204790 DOI: 10.1002/14651858.CD012334.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
15 Romanova VA, Goncharov AS, Terebilina NN, Moiseev VS. [Cardiac damage in liver cirrhosis in alcohol abusers]. Ter Arkh 2016;88:99-104. [PMID: 27636934 DOI: 10.17116/terarkh201688899-104] [Reference Citation Analysis]
16 European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57:399-420. [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004] [Cited by in Crossref: 400] [Cited by in F6Publishing: 351] [Article Influence: 40.0] [Reference Citation Analysis]
17 Xie YD, Feng B, Gao Y, Wei L. Characteristics of alcoholic liver disease and predictive factors for mortality of patients with alcoholic cirrhosis. Hepatobiliary Pancreat Dis Int 2013;12:594-601. [PMID: 24322744 DOI: 10.1016/s1499-3872(13)60094-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26:83-127. [PMID: 31918536 DOI: 10.3350/cmh.2019.0010n] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
19 Reddy SR, Mouchli M, Summey R, Walsh C, Mir A, Bierle L, Rubio MG. Outcomes of Young Patients With Alcoholic Cirrhosis After First Hospitalization for Cirrhosis: A Carilion Clinic Experience. Cureus 2021;13:e16695. [PMID: 34466325 DOI: 10.7759/cureus.16695] [Reference Citation Analysis]
20 Orr JG, Currie CJ, Berni E, Goel A, Moriarty KJ, Sinha A, Gordon F, Dethier A, Dillon JF, Clark K, Richardson P, Middleton P, Patel V, Shawcross D, Preedy H, Aspinall RJ, Hudson M. The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α. Liver Int 2016;36:1295-303. [PMID: 26950766 DOI: 10.1111/liv.13111] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
21 Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T, Nevens F. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59:2286-2298. [PMID: 24259407 DOI: 10.1002/hep.26939] [Cited by in Crossref: 153] [Cited by in F6Publishing: 151] [Article Influence: 19.1] [Reference Citation Analysis]
22 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Patients with liver cirrhosis show worse survival if decompensation occurs later during course of disease than at diagnosis. Scandinavian Journal of Gastroenterology 2018;53:475-81. [DOI: 10.1080/00365521.2018.1447599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
23 Wangler J, Claus S, Jansky M. Working relationship between primary and specialist care in analysing elevated liver values-a survey from the point of view of gastroenterologists. Wien Med Wochenschr 2021. [PMID: 34185218 DOI: 10.1007/s10354-021-00855-5] [Reference Citation Analysis]
24 Jang JY, Kim DJ. Epidemiology of alcoholic liver disease in Korea. Clin Mol Hepatol 2018;24:93-9. [PMID: 29544241 DOI: 10.3350/cmh.2017.0079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
25 Swaminathan M, Ellul MA, Cross TJ. Hepatic encephalopathy: current challenges and future prospects. Hepat Med. 2018;10:1-11. [PMID: 29606895 DOI: 10.2147/hmer.s118964] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 5.8] [Reference Citation Analysis]
26 Lee S, Uhm J, Kim J, Pak H, Lee M, Joung B. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. International Journal of Cardiology 2015;180:185-91. [DOI: 10.1016/j.ijcard.2014.11.183] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
27 Kim HI, Park SY, Shin HP. Incidence and management patterns of alcohol-related liver disease in Korea: a nationwide standard cohort study. Sci Rep 2021;11:6648. [PMID: 33758281 DOI: 10.1038/s41598-021-86197-z] [Reference Citation Analysis]
28 Eriksen CS, Kimer N, Suetta C, Møller S. Arm lean mass determined by dual-energy X-ray absorptiometry is superior to characterize skeletal muscle and predict sarcopenia-related mortality in cirrhosis. Am J Physiol Gastrointest Liver Physiol 2021;320:G729-40. [PMID: 33729006 DOI: 10.1152/ajpgi.00478.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Canbay A, Sowa JP. L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease. Drugs 2019;79:39-44. [PMID: 30706422 DOI: 10.1007/s40265-018-1020-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
30 D'amico G, Pasta L, Morabito A, D'amico M, Caltagirone M, Malizia G, Tinè F, Giannuoli G, Traina M, Vizzini G, Politi F, Luca A, Virdone R, Licata A, Pagliaro L. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014;39:1180-93. [DOI: 10.1111/apt.12721] [Cited by in Crossref: 238] [Cited by in F6Publishing: 181] [Article Influence: 29.8] [Reference Citation Analysis]
31 Avanceña ALV, Miller N, Uttal SE, Hutton DW, Mellinger JL. Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis. J Hepatol 2021;74:1286-94. [PMID: 33326815 DOI: 10.1016/j.jhep.2020.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
32 Garcia CS, Lima AS, La-Rotta EIG, Boin IFSF. Social support for patients undergoing liver transplantation in a Public University Hospital. Health Qual Life Outcomes 2018;16:35. [PMID: 29454342 DOI: 10.1186/s12955-018-0863-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
33 Li J, Feng D, Pang N, Zhao C, Gao L, Liu S, Li L. Controlling nutritional status score as a new indicator of overt hepatic encephalopathy in cirrhotic patients following transjugular intrahepatic portosystemic shunt. Clinical Nutrition 2022;41:560-6. [DOI: 10.1016/j.clnu.2021.12.036] [Reference Citation Analysis]
34 Yanny B, Winters A, Boutros S, Saab S. Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach. Clin Liver Dis 2019;23:607-23. [PMID: 31563214 DOI: 10.1016/j.cld.2019.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. American Journal of Gastroenterology 2018;113:254-64. [DOI: 10.1038/ajg.2017.440] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 9.8] [Reference Citation Analysis]
36 Wong M, Busuttil RW. Surgery in Patients with Portal Hypertension. Clin Liver Dis. 2019;23:755-780. [PMID: 31563221 DOI: 10.1016/j.cld.2019.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Tapper EB, Aberasturi D, Zhao Z, Hsu CY, Parikh ND. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther 2020;51:1397-405. [PMID: 32363684 DOI: 10.1111/apt.15749] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
38 Schlünsen ADM, Christiansen DH, Fredberg U, Vedsted P. Effectiveness of a 24-hour access outpatient clinic for patients with chronic conditions in hospital outpatient follow-up: a registry-based controlled cohort study of healthcare utilisation and mortality. Integ Health J 2022;4:e000069. [DOI: 10.1136/ihj-2020-000069] [Reference Citation Analysis]
39 Rubin JB, Sundaram V, Lai JC. Gender Differences Among Patients Hospitalized With Cirrhosis in the United States. J Clin Gastroenterol 2020;54:83-9. [PMID: 30807399 DOI: 10.1097/MCG.0000000000001192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
40 Listabarth S, Gmeiner A, Pruckner N, Vyssoki S, Wippel A, König D. When demand exceeds supply: Liver transplantation due to alcohol use disorder in Austria. Neuropsychiatr 2020;34:157-63. [PMID: 33141424 DOI: 10.1007/s40211-020-00364-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Singal AK, Arsalan A, Dunn W, Arab JP, Wong RJ, Kuo YF, Kamath PS, Shah VH. Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. Aliment Pharmacol Ther 2021;54:451-61. [PMID: 34247424 DOI: 10.1111/apt.16461] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Hung TH, Tseng CW, Tsai CC, Lay CJ, Tsai CC. A fourfold increase of oesophageal variceal bleeding in cirrhotic patients with a history of oesophageal variceal bleeding. Singapore Med J 2016;57:511-3. [PMID: 26768323 DOI: 10.11622/smedj.2015177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Formentin C, Zarantonello L, Mangini C, Frigo AC, Montagnese S, Merkel C. Clinical, neuropsychological and neurophysiological indices and predictors of hepatic encephalopathy (HE). Liver Int 2021;41:1070-82. [PMID: 33411388 DOI: 10.1111/liv.14785] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Hagström H, Thiele M, Roelstraete B, Söderling J, Ludvigsson JF. Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients. Gut 2021;70:170-9. [PMID: 32220902 DOI: 10.1136/gutjnl-2019-320446] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
45 Seraj SM, Campbell EJ, Argyropoulos SK, Wegermann K, Chung RT, Richter JM. Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy. World J Gastroenterol 2017; 23(37): 6868-6876 [PMID: 29085229 DOI: 10.3748/wjg.v23.i37.6868] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
46 Tu B, Bi J, Wu D, Zhao P, Shi L, Xie Y, Zhang X, Xu Z, Liu S, Wang X, Li X, Wang F, Qin E. Bloodstream infection due to Escherichia coli in liver cirrhosis patients: clinical features and outcomes. Oncotarget 2018;9:35780-9. [PMID: 30515269 DOI: 10.18632/oncotarget.23200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
47 Søgaard KK, Horváth-Puhó E, Montomoli J, Vilstrup H, Sørensen HT. Cirrhosis is Associated with an Increased 30-Day Mortality After Venous Thromboembolism. Clin Transl Gastroenterol. 2015;6:e97. [PMID: 26133110 DOI: 10.1038/ctg.2015.27] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
48 Trabut JB, Thépot V, Terris B, Sogni P, Nalpas B, Pol S. [Prognosis assessment of alcoholic liver disease: how and why?]. Presse Med 2014;43:124-34. [PMID: 24140195 DOI: 10.1016/j.lpm.2013.04.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
49 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69:154-181. [PMID: 29628280 DOI: 10.1016/j.jhep.2018.03.018] [Cited by in Crossref: 210] [Cited by in F6Publishing: 169] [Article Influence: 52.5] [Reference Citation Analysis]
50 Jepsen P. Comorbidity in cirrhosis. World J Gastroenterol 2014; 20(23): 7223-7230 [PMID: 24966593 DOI: 10.3748/wjg.v20.i23.7223] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
51 Nojkov B, Cappell MS. Distinctive aspects of peptic ulcer disease, Dieulafoy's lesion, and Mallory-Weiss syndrome in patients with advanced alcoholic liver disease or cirrhosis. World J Gastroenterol 2016; 22(1): 446-466 [PMID: 26755890 DOI: 10.3748/wjg.v22.i1.446] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
52 Jacques J, Carrier P, Debette-gratien M, Sobesky R, Loustaud-ratti V. Encéphalopathie hépatique. La Presse Médicale 2016;45:46-59. [DOI: 10.1016/j.lpm.2015.02.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
53 Kimer N, Wiese S, Mo S, Møller S, Bendtsen F. Advances in the treatment of portal hypertension in cirrhosis. Expert Rev Gastroenterol Hepatol 2016;10:961-9. [PMID: 26982499 DOI: 10.1586/17474124.2016.1166952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Xu R, Chang J. Progress in treatment of hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2015; 23(11): 1755-1762 [DOI: 10.11569/wcjd.v23.i11.1755] [Reference Citation Analysis]
55 Radisavljevic MM, Bjelakovic GB, Nagorni AV, Stojanovic MP, Radojkovicn MD, Jovic JZ, Ignjatovic AM, Radisavljevic MM, Simonovic MM. Predictors of Mortality in Long-Term Follow-Up of Patients with Terminal Alcoholic Cirrhosis: Is It Time to Accept Remodeled Scores? Med Princ Pract. 2017;26:169-175. [PMID: 27676412 DOI: 10.1159/000451057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
56 Hung TH, Tsai CC, Lee HF. Population-based study of Entecavir and long-term mortality in chronic hepatitis B-related decompensated liver cirrhosis. Clin Res Hepatol Gastroenterol 2019;43:694-9. [PMID: 30922728 DOI: 10.1016/j.clinre.2019.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
57 Chiang DJ, McCullough AJ. The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis. 2014;18:157-163. [PMID: 24274871 DOI: 10.1016/j.cld.2013.09.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
58 Driver RJ, Balachandrakumar V, Burton A, Shearer J, Downing A, Cross T, Morris E, Rowe IA. Validation of an algorithm using inpatient electronic health records to determine the presence and severity of cirrhosis in patients with hepatocellular carcinoma in England: an observational study. BMJ Open 2019;9:e028571. [PMID: 31292182 DOI: 10.1136/bmjopen-2018-028571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
59 Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, Baracos VE, Sawyer MB, Pang JX, Beaumont C, Esfandiari N, Myers RP. Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis. Clin Transl Gastroenterol 2015;6:e102. [PMID: 26181291 DOI: 10.1038/ctg.2015.31] [Cited by in Crossref: 155] [Cited by in F6Publishing: 138] [Article Influence: 22.1] [Reference Citation Analysis]
60 Berni E, Murphy D, Whitehouse J, Conway P, Di Maggio P, Currie CJ, Poole C. Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom. Current Medical Research and Opinion 2018;34:2001-8. [DOI: 10.1080/03007995.2018.1499506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Mattock R, Tripathi D, O'Neill F, Craig J, Tanner J, Patch D, Aithal G. Economic evaluation of covered stents for transjugular intrahepatic portosystemic stent shunt in patients with variceal bleeding and refractory ascites secondary to cirrhosis. BMJ Open Gastroenterol 2021;8:e000641. [PMID: 34429322 DOI: 10.1136/bmjgast-2021-000641] [Reference Citation Analysis]
62 Teschke R. Alcoholic Liver Disease: Alcohol Metabolism, Cascade of Molecular Mechanisms, Cellular Targets, and Clinical Aspects. Biomedicines 2018;6:E106. [PMID: 30424581 DOI: 10.3390/biomedicines6040106] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 11.5] [Reference Citation Analysis]
63 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
64 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. Aliment Pharmacol Ther 2019;49:1421-30. [DOI: 10.1111/apt.15255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
65 Flamm SL. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy. Am J Med Sci. 2018;356:296-303. [PMID: 30286824 DOI: 10.1016/j.amjms.2018.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
66 Glyn-Owen K, Böhning D, Parkes J, Roderick P, Buchanan R. The combined effect of alcohol and body mass index on risk of chronic liver disease: A systematic review and meta-analysis of cohort studies. Liver Int 2021;41:1216-26. [PMID: 33283434 DOI: 10.1111/liv.14754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Chautant F, Guillaume M, Robic MA, Cadranel JF, Peron JM, Lison H, Cool C, Bureau C, Duhalde V. Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy. World J Hepatol 2020; 12(1): 10-20 [PMID: 31984117 DOI: 10.4254/wjh.v12.i1.10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Ochoa-Sanchez R, Tamnanloo F, Rose CF. Hepatic Encephalopathy: From Metabolic to Neurodegenerative. Neurochem Res 2021. [PMID: 34129161 DOI: 10.1007/s11064-021-03372-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Grønbæk L, Vilstrup H, Deleuran B, Wiest R, Krag A, Jepsen P. Alcoholic Cirrhosis Increases Risk for Autoimmune Diseases: A Nationwide Registry-Based Cohort Study. Clin Gastroenterol Hepatol 2015;13:2017-22. [PMID: 26044312 DOI: 10.1016/j.cgh.2015.05.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
70 Childers RE, Ahn J. Diagnosis of Alcoholic Liver Disease: Key Foundations and New Developments. Clin Liver Dis 2016;20:457-71. [PMID: 27373609 DOI: 10.1016/j.cld.2016.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
71 Labenz C, Wörns MA, Adarkwah CC, Galle PR, Schattenberg JM, Kostev K. Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study. Aliment Pharmacol Ther 2020;52:1042-50. [PMID: 32729625 DOI: 10.1111/apt.16008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Incidence, clinical presentation and mortality of liver cirrhosis in Southern Sweden: a 10-year population-based study. Aliment Pharmacol Ther. 2016;43:1330-1339. [PMID: 27091240 DOI: 10.1111/apt.13635] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
73 Gabriel MM, Kircheis G, Hardtke S, Markwardt D, Buggisch P, Mix H, Grüngreiff K, Welzel TM, Kälsch J, Hartmann H, Gerbes AL, Karpowitz MV, Seeliger B, Wedemeyer H, Weissenborn K. Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study. European Journal of Gastroenterology & Hepatology 2021;33:1185-93. [DOI: 10.1097/meg.0000000000001822] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 D'Amico G, Bernardi M, Angeli P. TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS. J Hepatol 2021:S0168-8278(21)00438-4. [PMID: 34157322 DOI: 10.1016/j.jhep.2021.06.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
76 Baki JA, Tapper EB. Contemporary Epidemiology of Cirrhosis. Curr Treat Options Gastroenterol 2019;17:244-53. [PMID: 30949926 DOI: 10.1007/s11938-019-00228-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
77 Njei B, McCarty TR, Laine L. Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding. J Gastroenterol Hepatol 2017;32:852-8. [PMID: 27624167 DOI: 10.1111/jgh.13593] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
78 Osman MA, Sayed MM, Mansour KA, Saleh SA, Ibrahim WA, Abdelhakam SM, Bahaa M, Yousry WA, Elbaz HS, Mikhail RN, Hassan AM, Elsayed EH, Mahmoud DA. Reversibility of minimal hepatic encephalopathy following liver transplantation in Egyptian cirrhotic patients. World J Hepatol 2016; 8(30): 1279-1286 [PMID: 27843538 DOI: 10.4254/wjh.v8.i30.1279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
79 Romeiro FG, Augusti L. Nutritional assessment in cirrhotic patients with hepatic encephalopathy. World J Hepatol 2015; 7(30): 2940-2954 [PMID: 26730273 DOI: 10.4254/wjh.v7.i30.2940] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
80 Piotrowski D, Boroń-Kaczmarska A. Bacterial infections and hepatic encephalopathy in liver cirrhosis-prophylaxis and treatment. Adv Med Sci 2017;62:345-56. [PMID: 28514703 DOI: 10.1016/j.advms.2016.11.009] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
81 Labenz C, Toenges G, Schattenberg JM, Nagel M, Huber Y, Marquardt JU, Labenz J, Galle PR, Wörns MA. Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies. Clin Transl Gastroenterol 2020;11:e00172. [PMID: 32568474 DOI: 10.14309/ctg.0000000000000172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Asrani SK, Kamath PS. Natural history of cirrhosis. Curr Gastroenterol Rep. 2013;15:308. [PMID: 23314828 DOI: 10.1007/s11894-012-0308-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
83 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406-460. [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024] [Cited by in Crossref: 660] [Cited by in F6Publishing: 520] [Article Influence: 165.0] [Reference Citation Analysis]
84 Shawcross DL, Dunk AA, Jalan R, Kircheis G, de Knegt RJ, Laleman W, Ramage JK, Wedemeyer H, Morgan IE; New Insights Steering Committee. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol. 2016;28:146-152. [PMID: 26600154 DOI: 10.1097/meg.0000000000000529] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
85 American Association for the Study of Liver Diseases. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61:642-659. [PMID: 25015420 DOI: 10.1016/j.jhep.2014.05.042] [Cited by in Crossref: 212] [Cited by in F6Publishing: 164] [Article Influence: 26.5] [Reference Citation Analysis]
86 Lucey MR. Alcohol-Associated Cirrhosis. Clin Liver Dis 2019;23:115-26. [PMID: 30454826 DOI: 10.1016/j.cld.2018.09.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
87 Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA. Clinical outcomes of compensated and decompensated cirrhosis: A long term study. World J Hepatol 2014; 6(7): 504-512 [PMID: 25068002 DOI: 10.4254/wjh.v6.i7.504] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
88 Gao F, Li X, Wan G, Li Y, Zhang Q, Liu Y, Liu H, Li H, Wang X. Development and external validation of a prognostic nomogram for acute decompensation of chronic hepatitis B cirrhosis. BMC Gastroenterol. 2018;18:179. [PMID: 30509201 DOI: 10.1186/s12876-018-0911-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
89 Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018;5:CD012410. [PMID: 29762873 DOI: 10.1002/14651858.cd012410.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
90 Wiegand J, Kühne M, Pradat P, Mössner J, Trepo C, Tillmann HL. Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis. Aliment Pharmacol Ther. 2012;35:1443-1450. [PMID: 22530565 DOI: 10.1111/j.1365-2036.2012.05108.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
91 Kimer N, Feineis M, Møller S, Bendtsen F. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. Scand J Gastroenterol. 2015;50:129-137. [PMID: 25113796 DOI: 10.3109/00365521.2014.948053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
92 Moon AM, Jiang Y, Rogal SS, Tapper EB, Lieber SR, Barritt AS 4th. Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis. Aliment Pharmacol Ther 2020;51:652-60. [PMID: 31960985 DOI: 10.1111/apt.15639] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
93 Holland-Bill L, Christiansen CF, Gammelager H, Mortensen RN, Pedersen L, Sørensen HT. Chronic liver disease and 90-day mortality in 21,359 patients following peptic ulcer bleeding--a Nationwide Cohort Study. Aliment Pharmacol Ther. 2015;41:564-572. [PMID: 25588862 DOI: 10.1111/apt.13073] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
94 Hung TH, Tsai CC, Hsieh YH, Tsai CC, Tseng CW, Tseng KC. The Effect of the First Spontaneous Bacterial Peritonitis Event on the Mortality of Cirrhotic Patients with Ascites: A Nationwide Population-Based Study in Taiwan. Gut Liver 2016;10:803-7. [PMID: 27563023 DOI: 10.5009/gnl13468] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
95 Hung TH, Tsai CC, Lee HF. Effects of poor hepatic reserve in cirrhotic patients with bacterial infections: A population-based study. Ci Ji Yi Xue Za Zhi 2020;32:47-52. [PMID: 32110520 DOI: 10.4103/tcmj.tcmj_142_18] [Reference Citation Analysis]
96 Degré D, Stauber RE, Englebert G, Sarocchi F, Verset L, Rainer F, Spindelboeck W, Njimi H, Trépo E, Gustot T, Lackner C, Deltenre P, Moreno C. Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey's discriminant function <32. J Hepatol 2020;72:636-42. [PMID: 31954208 DOI: 10.1016/j.jhep.2019.12.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
97 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650-2666. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 102] [Cited by in F6Publishing: 110] [Article Influence: 34.0] [Reference Citation Analysis]
98 Kimer N, Naver AV, Thiele M, Krag A, Gluud LL; Cochrane Hepato-Biliary Group. Beta-blockers alone or in combination with isosorbide mononitrate for secondary prevention of bleeding from gastro-esophageal varices in adults with cirrhosis and gastro-oesophageal varices. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012127] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
99 Yoon U, Topper J, Goldhammer J. Preoperative Evaluation and Anesthetic Management of Patients With Liver Cirrhosis Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth 2020:S1053-0770(20)30816-8. [PMID: 32891522 DOI: 10.1053/j.jvca.2020.08.022] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ, Volk ML, Blow FC, Lok ASF. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018;68:872-882. [PMID: 29579356 DOI: 10.1002/hep.29887] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 20.8] [Reference Citation Analysis]
101 El-Gohary M, Moore M, Roderick P, Watkins E, Dash J, Reinson T, Newell C, Kim M, Stuart B, Becque T, Sheron N. Local care and treatment of liver disease (LOCATE) - A cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care. PLoS One 2018;13:e0208798. [PMID: 30576330 DOI: 10.1371/journal.pone.0208798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
102 Bajaj JS, Barbara G, DuPont HL, Mearin F, Gasbarrini A, Tack J. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Dig Liver Dis 2018;50:741-9. [PMID: 29807873 DOI: 10.1016/j.dld.2018.04.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
103 Serra-burriel M, Graupera I, Torán P, Thiele M, Roulot D, Wai-sun Wong V, Neil Guha I, Fabrellas N, Arslanow A, Expósito C, Hernández R, Lai-hung Wong G, Harman D, Darwish Murad S, Krag A, Pera G, Angeli P, Galle P, Aithal GP, Caballeria L, Castera L, Ginès P, Lammert F. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. Journal of Hepatology 2019;71:1141-51. [DOI: 10.1016/j.jhep.2019.08.019] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 13.7] [Reference Citation Analysis]
104 Strebel H, Haller B, Sohn M, Schepp W, Gundling F. Role of Brain Biomarkers S-100-Beta and Neuron-Specific Enolase for Detection and Follow-Up of Hepatic Encephalopathy in Cirrhosis before, during and after Treatment with L-Ornithine-L-Aspartate. GE Port J Gastroenterol 2020;27:391-403. [PMID: 33251288 DOI: 10.1159/000507225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Jepsen P, Ott P. Hepatocellular carcinoma surveillance in patients with alcoholic cirrhosis. Expert Review of Gastroenterology & Hepatology 2014;6:651-3. [DOI: 10.1586/egh.12.59] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
106 Bian J, Wang A, Lin J, Wu L, Huang H, Wang S, Yang X, Lu X, Xu Y, Zhao H. Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis. Medicine (Baltimore) 2017;96:e6723. [PMID: 28445288 DOI: 10.1097/MD.0000000000006723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
107 Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749-1761. [PMID: 24480518 DOI: 10.1016/s0140-6736(14)60121-5] [Cited by in Crossref: 801] [Cited by in F6Publishing: 395] [Article Influence: 100.1] [Reference Citation Analysis]
108 Yoo T, Lee KW, Yi NJ, Hong SK, Lee JM, Kim H, Lim J, Seo S, Suh KS. Impact of PNPLA3 (rs738409-G) polymorphism on post-transplant outcomes after liver transplantation for alcohol-related liver disease. Clin Transplant 2020;34:e14011. [PMID: 32557704 DOI: 10.1111/ctr.14011] [Reference Citation Analysis]
109 Hung TH, Tsai CC, Lee HF. Statin use in cirrhotic patients with infectious diseases: A population-based study. PLoS One 2019;14:e0215839. [PMID: 31017946 DOI: 10.1371/journal.pone.0215839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
110 Wangler J, Jansky M. [Evaluation of abnormal liver chemistries in primary care - A survey on the prerequisites, procedure and challenges faced by general practitioners]. Z Gastroenterol 2020. [PMID: 32838434 DOI: 10.1055/a-1213-6491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Kornerup LS, Pflugrad H, Weissenborn K, Vilstrup H, Dam G. Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy? Hepat Med 2019;11:41-6. [PMID: 31040728 DOI: 10.2147/HMER.S144667] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
112 Wernberg CW, Schaffalitzky de Muckadell OB, Vilstrup H, M Lauridsen M. Prediction of overt hepatic encephalopathy by the continuous reaction time method and the portosystemic encephalopathy syndrome test in clinically mentally unimpaired patients with cirrhosis. PLoS One 2019;14:e0226283. [PMID: 31830113 DOI: 10.1371/journal.pone.0226283] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Romeiro FG, Ietsugu MDV, Franzoni LC, Augusti L, Alvarez M, Santos LAA, Lima TB, Koga KH, Moriguchi SM, Caramori CA, Silva GF, Betting LEGG. Which of the branched-chain amino acids increases cerebral blood flow in hepatic encephalopathy? A double-blind randomized trial. Neuroimage Clin 2018;19:302-10. [PMID: 30013913 DOI: 10.1016/j.nicl.2018.03.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012;32:1407-1414. [PMID: 22679906 DOI: 10.1111/j.1478-3231.2012.02830.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 105] [Article Influence: 13.8] [Reference Citation Analysis]
116 Italian Association for the Study of the Liver (AISF). Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2021;53:1089-104. [PMID: 34321192 DOI: 10.1016/j.dld.2021.06.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
117 Piechota M, Piechota A. An Evaluation of the Usefulness of Extracorporeal Liver Support Techniques in Patients Hospitalized in the ICU for Severe Liver Dysfunction Secondary to Alcoholic Liver Disease. Hepat Mon. 2016;16:e34127. [PMID: 27642344 DOI: 10.5812/hepatmon.34127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
118 Santos SGRD, Mattos AA, Guimarães MM, Boger BS, Coral GP. Alcohol Consumption Influences Clinical Outcome in Patients Admitted to a Referral Center for Liver Disease. Ann Hepatol 2018;17:470-5. [PMID: 29735785 DOI: 10.5604/01.3001.0011.7391] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
119 Tapper EB, Parikh ND, Sengupta N, Mellinger J, Ratz D, Lok AS, Su GL. A risk score to predict the development of hepatic encephalopathy in a population‐based cohort of patients with cirrhosis. Hepatology 2018;68:1498-507. [DOI: 10.1002/hep.29628] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 8.5] [Reference Citation Analysis]
120 Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Risum N, Vilstrup H. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013;143:1263-1268. [PMID: 23739310 DOI: 10.3945/jn.113.174375] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
121 Kondo T, Maruyama H, Sekimoto T, Shimada T, Takahashi M, Okugawa H, Yokosuka O. Impact of portal hemodynamics on Doppler ultrasonography for predicting decompensation and long-term outcomes in patients with cirrhosis. Scand J Gastroenterol. 2016;51:236-244. [PMID: 26357874 DOI: 10.3109/00365521.2015.1081275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
122 Hasan LZ, Wu GY. Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol 2021;9:749-59. [PMID: 34722190 DOI: 10.14218/JCTH.2021.00102] [Reference Citation Analysis]
123 Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393:1597-608. [PMID: 30910320 DOI: 10.1016/S0140-6736(18)31875-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 27] [Article Influence: 35.0] [Reference Citation Analysis]
124 Alvarez MA, Cirera I, Solà R, Bargalló A, Morillas RM, Planas R. Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. J Clin Gastroenterol. 2011;45:906-911. [PMID: 21814145 DOI: 10.1097/mcg.0b013e3182284e13] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
125 Shi D, Zhou Z, Dai Y, Pan X, Cao Q. Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis. Clin Drug Investig 2019;39:847-56. [DOI: 10.1007/s40261-019-00810-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
126 Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, Vilstrup H, Jalan R. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73:1526-1547. [PMID: 33097308 DOI: 10.1016/j.jhep.2020.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
127 Costa D, Simbrunner B, Jachs M, Hartl L, Bauer D, Paternostro R, Schwabl P, Scheiner B, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.J Hepatol. 2021;74:819-828. [PMID: 33075344 DOI: 10.1016/j.jhep.2020.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
128 Gustot T, Stadlbauer V, Laleman W, Alessandria C, Thursz M. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. J Hepatol 2021;75 Suppl 1:S36-48. [PMID: 34039491 DOI: 10.1016/j.jhep.2020.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
129 Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123-32. [DOI: 10.1111/apt.12803] [Cited by in Crossref: 109] [Cited by in F6Publishing: 77] [Article Influence: 13.6] [Reference Citation Analysis]
130 Mikkelsen MR, Hendriksen C, Schiødt FV, Rydahl-hansen S. Coping and rehabilitation in alcoholic liver disease patients after hepatic encephalopathy - in interaction with professionals and relatives. J Clin Nurs 2015;24:3627-37. [DOI: 10.1111/jocn.13006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
131 Jepsen P, Kraglund F, West J, Villadsen GE, Sørensen HT, Vilstrup H. Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis. J Hepatol 2020;73:1030-6. [PMID: 32512015 DOI: 10.1016/j.jhep.2020.05.043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
132 Labenz C, Toenges G, Huber Y, Nagel M, Marquardt JU, Schattenberg JM, Galle PR, Labenz J, Wörns MA. Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. Aliment Pharmacol Ther 2019;50:1112-9. [PMID: 31583743 DOI: 10.1111/apt.15515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
133 Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. 2016;43 Suppl 1:11-26. [PMID: 26618922 DOI: 10.1111/apt.13435] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
134 Thomsen KL, Macnaughtan J, Tritto G, Mookerjee RP, Jalan R. Clinical and Pathophysiological Characteristics of Cirrhotic Patients with Grade 1 and Minimal Hepatic Encephalopathy. PLoS One. 2016;11:e0146076. [PMID: 26745876 DOI: 10.1371/journal.pone.0146076] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
135 Ye JF, Ju J. Rifaximin for prevention and treatment of hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2015; 23(7): 1090-1096 [DOI: 10.11569/wcjd.v23.i7.1090] [Reference Citation Analysis]
136 Jepsen P, Christensen J, Weissenborn K, Watson H, Vilstrup H. Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort study. BMC Gastroenterol 2016;16:77. [PMID: 27457247 DOI: 10.1186/s12876-016-0487-3] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
137 Mangas-Sanjuan C, Martínez-Moreno B, Bozhychko M, Compañy L, Martinez J, Ruiz F, Casellas JA, Aparicio JR. Over-the-scope clip for acute esophageal variceal bleeding. Dig Endosc 2019;31:712-6. [PMID: 31330068 DOI: 10.1111/den.13493] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
138 Deleuran T, Vilstrup H, Jepsen P. Decreasing Mortality Among Danish Alcoholic Cirrhosis Patients: A Nationwide Cohort Study. American Journal of Gastroenterology 2016;111:817-22. [DOI: 10.1038/ajg.2016.107] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
139 Masson S, Emmerson I, Henderson E, Fletcher EH, Burt AD, Day CP, Stewart SF. Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease. Liver Int. 2014;34:235-242. [PMID: 23834275 DOI: 10.1111/liv.12242] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
140 Hung TH, Tsai CC, Tseng KC, Tseng C-, Hsieh YH, Tsai CC, Lee HF. High Mortality of Cirrhotic Patients With End-Stage Renal Disease. Medicine (Baltimore) 2016;95:e3057. [PMID: 26962834 DOI: 10.1097/MD.0000000000003057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Deleuran T, Schmidt M, Vilstrup H, Jepsen P. Time‐dependent incidence and risk for myocardial infarction in patients with alcoholic cirrhosis. Eur J Clin Invest 2020;50. [DOI: 10.1111/eci.13205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
142 Rivera C, Chevalier B, Fabre E, Pricopi C, Badia A, Arame A, Foucault C, Dujon A, Le Pimpec Barthes F, Riquet M. [Lung cancer surgery and cirrhosis]. Rev Pneumol Clin 2015;71:12-9. [PMID: 25687820 DOI: 10.1016/j.pneumo.2014.09.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
143 Salehi S, Tranah TH, Lim S, Heaton N, Heneghan M, Aluvihare V, Patel VC, Shawcross DL. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. Aliment Pharmacol Ther 2019;50:435-41. [PMID: 31169941 DOI: 10.1111/apt.15326] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
144 Tapper EB, Henderson JB, Parikh ND, Ioannou GN, Lok AS. Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis. Hepatol Commun 2019;3:1510-9. [PMID: 31701074 DOI: 10.1002/hep4.1425] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
145 Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4:16. [PMID: 30115921 DOI: 10.1038/s41572-018-0014-7] [Cited by in Crossref: 191] [Cited by in F6Publishing: 195] [Article Influence: 47.8] [Reference Citation Analysis]
146 Krishnarao A, Gordon FD. Prognosis of Hepatic Encephalopathy. Clin Liver Dis 2020;24:219-29. [PMID: 32245529 DOI: 10.1016/j.cld.2020.01.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Gil-Gómez A, Ampuero J, Rojas Á, Gallego-Durán R, Muñoz-Hernández R, Rico MC, Millán R, García-Lozano R, Francés R, Soriano G, Romero-Gómez M. Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. Am J Gastroenterol 2021;116:1238-47. [PMID: 33852451 DOI: 10.14309/ajg.0000000000001164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Labenz C, Kostev K, Galle PR, Wörns MA, Schattenberg JM. Prescription rates of common medications in patients with decompensated cirrhosis in Germany. Z Gastroenterol 2021. [PMID: 34820806 DOI: 10.1055/a-1676-4822] [Reference Citation Analysis]
149 Gellad ZF, Muir AJ, McHutchison JG, Sievert W, Sharara AI, Brown KA, Flisiak R, Jacobson IM, Kershenobich D, Manns MP, Schulman KA, Reed SD. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. Value Health 2012;15:876-86. [PMID: 22999138 DOI: 10.1016/j.jval.2012.06.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
150 Liu A, Perumpail RB, Kumari R, Younossi ZM, Wong RJ, Ahmed A. Advances in cirrhosis: Optimizing the management of hepatic encephalopathy. World J Hepatol 2015; 7(29): 2871-2879 [PMID: 26692331 DOI: 10.4254/wjh.v7.i29.2871] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
151 Torruellas C, French SW, Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol 2014; 20(33): 11684-11699 [PMID: 25206273 DOI: 10.3748/wjg.v20.i33.11684] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
152 Dyson JK, Rajasekhar P, Wetten A, Ashraf HH, Ng S, Paremal S, Baqai MF, Lamb CA, Masson S, Hudson M, Dipper C, Cowlam S, Hussaini H, McPherson S. Implementation of a 'care bundle' improves the management of patients admitted to hospital with decompensated cirrhosis. Aliment Pharmacol Ther 2016;44:1030-8. [PMID: 27666418 DOI: 10.1111/apt.13806] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
153 Lee H, Oh S, Yu JH, Kim J, Yoon S, Ryu HG. Risk Factors of Postoperative Delirium in the Intensive Care Unit After Liver Transplantation. World J Surg 2018;42:2992-9. [DOI: 10.1007/s00268-018-4563-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
154 Song DS. [Medical Treatment of Alcoholic Liver Disease]. Korean J Gastroenterol 2020;76:65-70. [PMID: 32839368 DOI: 10.4166/kjg.2020.76.2.65] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Kornerup LS, Gluud LL, Vilstrup H, Dam G. Update on the Therapeutic Management of Hepatic Encephalopathy. Curr Gastroenterol Rep. 2018;20:21. [PMID: 29644492 DOI: 10.1007/s11894-018-0627-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
156 Mousa N, Abdel-Razik A, Sheta T, G Deiab A, Habib A, Diasty M, Eldesoky A, Taha A, Mousa E, Yassen A, Fathy A, Elgamal A. Endoscopic management of acute oesophageal variceal bleeding within 12 hours of admission is superior to 12-24 hours. Br J Biomed Sci 2021;78:130-4. [PMID: 33305686 DOI: 10.1080/09674845.2020.1857049] [Reference Citation Analysis]
157 Kim W. [Diagnostic and therapeutic strategies for severe alcoholic hepatitis]. Korean J Gastroenterol 2015;65:4-11. [PMID: 25603848 DOI: 10.4166/kjg.2015.65.1.4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
158 Hermos JA, Altincatal A, Weber HC, Grotzinger K, Smoot KJ, Cho K, Gagnon DR, Lawler EV. Thrombocytopenia and bleeding in veterans with non-hepatitis C-related chronic liver disease. Dig Dis Sci 2013;58:562-73. [PMID: 23010745 DOI: 10.1007/s10620-012-2404-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
159 Jeong JH, Park IS, Kim DH, Kim SC, Kang C, Lee SH, Kim TY, Lee SB. CLIF-SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis. Medicine (Baltimore). 2016;95:e3935. [PMID: 27367990 DOI: 10.1097/md.0000000000003935] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
160 Dhiman RK, Thumburu KK, Verma N, Chopra M, Rathi S, Dutta U, Singal AK, Taneja S, Duseja A, Singh M. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.Clin Gastroenterol Hepatol. 2020;18:800-812.e25. [PMID: 31476436 DOI: 10.1016/j.cgh.2019.08.047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
161 Gluud LL, Jeyaraj R, Morgan MY. Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy. J Clin Exp Hepatol 2019;9:354-61. [PMID: 31360028 DOI: 10.1016/j.jceh.2019.02.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Castera L. Screening for liver fibrosis in primary care: Focus on subjects above 40 and with metabolic risk factors. United European Gastroenterol J 2021. [PMID: 34228905 DOI: 10.1002/ueg2.12120] [Reference Citation Analysis]
163 Malik A, Kardashian AA, Zakharia K, Bowlus CL, Tabibian JH. Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. Liver Res 2019;3:118-27. [PMID: 32042471 DOI: 10.1016/j.livres.2019.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
164 Lombardi R, Buzzetti E, Roccarina D, Tsochatzis EA. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. World J Gastroenterol 2015; 21(39): 11044-11052 [PMID: 26494961 DOI: 10.3748/wjg.v21.i39.11044] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
165 Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: The importance of multistate models and competing risks analysis. Hepatology 2015;62:292-302. [DOI: 10.1002/hep.27598] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 13.3] [Reference Citation Analysis]
166 Nabavi SF, Daglia M, Moghaddam AH, Habtemariam S, Nabavi SM. Curcumin and Liver Disease: from Chemistry to Medicine: Curcumin and liver disease…. Comprehensive Reviews in Food Science and Food Safety 2014;13:62-77. [DOI: 10.1111/1541-4337.12047] [Cited by in Crossref: 97] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
167 Seitz HK, Neuman MG. The History of Alcoholic Liver Disease: From an Unrecognized Disease to One of the Most Frequent Diseases in Hepatology. J Clin Med 2021;10:858. [PMID: 33669694 DOI: 10.3390/jcm10040858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Gantzel RH, Kjær MB, Laursen TL, Kazankov K, George J, Møller HJ, Grønbæk H. Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. Front Med (Lausanne) 2020;7:615599. [PMID: 33490096 DOI: 10.3389/fmed.2020.615599] [Reference Citation Analysis]
169 D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68:563-576. [PMID: 29111320 DOI: 10.1016/j.jhep.2017.10.020] [Cited by in Crossref: 116] [Cited by in F6Publishing: 97] [Article Influence: 23.2] [Reference Citation Analysis]
170 Marot A, Henrion J, Knebel JF, Moreno C, Deltenre P. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study. PLoS One 2017;12:e0186715. [PMID: 29077714 DOI: 10.1371/journal.pone.0186715] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
171 de Carvalho JR, Villela-Nogueira CA, Luiz RR, Guzzo PL, da Silva Rosa JM, Rocha E, Moraes Coelho HS, de Mello Perez R. Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites. J Clin Gastroenterol. 2012;46:e21-e26. [PMID: 21934526 DOI: 10.1097/mcg.0b013e31822e8e12] [Cited by in Crossref: 68] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
172 Weiss N, Tripon S, Lodey M, Guiller E, Junot H, Monneret D, Mayaux J, Brisson H, Mallet M, Rudler M, Imbert-bismut F, Thabut D; the Brain-Liver Pitié-Salpêtrière Study Group (BLIPS). Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study. Fundam Clin Pharmacol 2018;32:209-15. [DOI: 10.1111/fcp.12340] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
173 Soto M, Sampietro-Colom L, Lasalvia L, Mira A, Jiménez W, Navasa M. Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. World J Gastroenterol 2017; 23(17): 3163-3173 [PMID: 28533673 DOI: 10.3748/wjg.v23.i17.3163] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
174 Kim W, Kim DJ. Severe alcoholic hepatitis-current concepts, diagnosis and treatment options. World J Hepatol 2014; 6(10): 688-695 [PMID: 25349640 DOI: 10.4254/wjh.v6.i10.688] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
175 Labenz C, Nagel M, Toenges G, Kuchen R, Schattenberg JM, Hilscher M, Huber Y, Marquardt JU, Labenz J, Galle PR, Wörns MA. Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis. Eur J Intern Med 2020;82:83-9. [PMID: 32873457 DOI: 10.1016/j.ejim.2020.08.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
176 Kimer N, Grønbæk H, Fred RG, Hansen T, Deshmukh AS, Mann M, Bendtsen F. Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial. BMJ Open 2020;10:e035284. [PMID: 31980514 DOI: 10.1136/bmjopen-2019-035284] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Erard-Poinsot D, Dharancy S, Hilleret MN, Faure S, Lamblin G, Chambon-Augoyard C, Donnadieu-Rigole H, Lassailly G, Boillot O, Ursic-Bedoya J, Guillaud O, Leroy V, Pageaux GP, Dumortier J. Natural History of Recurrent Alcohol-Related Cirrhosis After Liver Transplantation: Fast and Furious. Liver Transpl 2020;26:25-33. [PMID: 31562696 DOI: 10.1002/lt.25647] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
178 Sharma P, Sharma BC. Management Patterns of Hepatic Encephalopathy: A Nationwide Survey in India. J Clin Exp Hepatol 2015;5:199-203. [PMID: 26628837 DOI: 10.1016/j.jceh.2015.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
179 Elsaid MI, Rustgi VK. Epidemiology of Hepatic Encephalopathy. Clinics in Liver Disease 2020;24:157-74. [DOI: 10.1016/j.cld.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
180 Kimer N, Krag A, Gluud LL. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Prefer Adherence. 2014;8:331-338. [PMID: 24672227 DOI: 10.2147/PPA.S41565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
181 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol. 2013;19:216-254. [PMID: 24133661 DOI: 10.3350/cmh.2013.19.3.216] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
182 Jepsen P, Ott P, Andersen PK, Vilstrup H. The clinical course of alcoholic cirrhosis: effects of hepatic metabolic capacity, alcohol consumption, and hyponatremia--a historical cohort study. BMC Res Notes 2012;5:509. [PMID: 22988833 DOI: 10.1186/1756-0500-5-509] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
183 Dhiman RK, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, Khattri A, Malhotra S, Duseja A, Chawla YK. Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis: A Randomized, Controlled Trial. Gastroenterology 2014;147:1327-1337.e3. [DOI: 10.1053/j.gastro.2014.08.031] [Cited by in Crossref: 180] [Cited by in F6Publishing: 160] [Article Influence: 22.5] [Reference Citation Analysis]
184 Kimer N, Gluud LL, Pedersen JS, Tavenier J, Møller S, Bendtsen F. The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis. Transl Gastroenterol Hepatol 2021;6:8. [PMID: 33409402 DOI: 10.21037/tgh.2020.02.14] [Reference Citation Analysis]
185 Opoku YK, Liu Z, Afrifa J, Kumi AK, Liu H, Ghartey-Kwansah G, Koranteng H, Jiang X, Ren G, Li D. Fibroblast Growth Factor-21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells. EXCLI J 2020;19:567-81. [PMID: 32483404 DOI: 10.17179/excli2020-1287] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
186 Ma JL, He LL, Li P, Jiang Y, Hu JL, Zhou YL, Liang XX, Wei HS. Clinical Features and Outcomes of Repeated Endoscopic Therapy for Esophagogastric Variceal Hemorrhage in Cirrhotic Patients: Ten-Year Real-World Analysis. Gastroenterol Res Pract 2020;2020:5747563. [PMID: 32508912 DOI: 10.1155/2020/5747563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Addolorato G, Abenavoli L, Dallio M, Federico A, Germani G, Gitto S, Leandro G, Loguercio C, Marra F, Stasi E. Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2020;52:374-91. [PMID: 32001151 DOI: 10.1016/j.dld.2019.12.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
188 Kronsten VT, Shawcross DL. Hepatic encephalopathy and depression in chronic liver disease: is the common link systemic inflammation? Anal Biochem 2021;:114437. [PMID: 34715068 DOI: 10.1016/j.ab.2021.114437] [Reference Citation Analysis]
189 Lanthier N, Rubbia-Brandt L, Lin-Marq N, Clément S, Frossard JL, Goossens N, Hadengue A, Spahr L. Hepatic cell proliferation plays a pivotal role in the prognosis of alcoholic hepatitis. J Hepatol. 2015;63:609-621. [PMID: 25872168 DOI: 10.1016/j.jhep.2015.04.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
190 Kendrick S, Day C. Natural history and factors influencing the course of alcohol-related liver disease. Clin Liver Dis (Hoboken) 2013;2:61-3. [PMID: 30992825 DOI: 10.1002/cld.145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
191 Asphaug L, Thiele M, Krag A, Melberg HO. Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis.Hepatology. 2020;71:2093-2104. [PMID: 31595545 DOI: 10.1002/hep.30979] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
192 Rudler M, Weiss N, Bouzbib C, Thabut D. Diagnosis and Management of Hepatic Encephalopathy. Clin Liver Dis 2021;25:393-417. [PMID: 33838857 DOI: 10.1016/j.cld.2021.01.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
193 Lee HW, Yip TC, Tse YK, Wong GL, Kim BK, Kim SU, Park JY, Kim DY, Chan HL, Ahn SH, Wong VW. Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2020;. [PMID: 32889148 DOI: 10.1016/j.cgh.2020.08.064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
194 Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther. 2010;32:1343-1350. [PMID: 21050236 DOI: 10.1111/j.1365-2036.2010.04473.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
195 Morrison D, Sgrillo J, Daniels LH. Managing alcoholic liver disease. Nursing 2014;44:30-40. [DOI: 10.1097/01.nurse.0000454950.13699.e0] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
196 Senanayake SM, Niriella MA, Weerasinghe SK, Kasturiratne A, de Alwis JP, de Silva AP, Dassanayake AS, de Silva HJ. Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study. BMC Res Notes. 2012;5:663. [PMID: 23198995 DOI: 10.1186/1756-0500-5-663] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
197 Askgaard G, Neermark S, Leon DA, Kjær MS, Tolstrup JS. Hospital contacts with alcohol problems prior to liver cirrhosis or pancreatitis diagnosis. World J Hepatol 2017; 9(36): 1332-1339 [PMID: 29359016 DOI: 10.4254/wjh.v9.i36.1332] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
198 Montomoli J, Erichsen R, Nørgaard M, Høyer M, Hansen JB, Jacobsen JB. Survival of patients with primary liver cancer in central and northern Denmark, 1998-2009. Clin Epidemiol 2011;3 Suppl 1:3-10. [PMID: 21814464 DOI: 10.2147/CLEP.S20623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
199 Jepsen P, Lash TL, Vilstrup H. The clinical course of alcoholic cirrhosis: development of comorbid diseases. A Danish nationwide cohort study. Liver Int. 2016;36:1696-1703. [PMID: 27124269 DOI: 10.1111/liv.13151] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
200 Bannister CA, Orr JG, Reynolds AV, Hudson M, Conway P, Radwan A, Morgan CL, Currie CJ. Natural History of Patients Taking Rifaximin-α for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data. Clin Ther 2016;38:1081-1089.e4. [PMID: 27136714 DOI: 10.1016/j.clinthera.2016.03.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
201 Pelle J, Castelli FA, Rudler M, Alioua I, Colsch B, Fenaille F, Junot C, Thabut D, Weiss N. Metabolomics in the understanding and management of hepatic encephalopathy. Anal Biochem 2022;636:114477. [PMID: 34808106 DOI: 10.1016/j.ab.2021.114477] [Reference Citation Analysis]
202 Rodríguez M, González-Diéguez ML, Varela M, Cadahía V, Andrés-Vizán SM, Mesa A, Castaño A, Alvarez-Navascués C. Impact of Alcohol Abstinence on the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Cirrhosis. Am J Gastroenterol 2021. [PMID: 34569986 DOI: 10.14309/ajg.0000000000001399] [Reference Citation Analysis]
203 Kim SH, Ko IG, Jin JJ, Hwang L, Kim BK, Baek SS. Study on the pathogenesis of liver injury caused by alcohol and drugs. J Exerc Rehabil 2021;17:319-23. [PMID: 34805020 DOI: 10.12965/jer.2142530.265] [Reference Citation Analysis]
204 Dam Fialla A, Schaffalitzky de Muckadell OB, Touborg Lassen A. Incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2012;47:702-709. [PMID: 22428859 DOI: 10.3109/00365521.2012.661759] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
205 Jepsen P, Tapper EB, Deleuran T, Kazankov K, Askgaard G, Sørensen HT, Vilstrup H, West J. Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation-wide Cohort Study. Hepatology 2021. [PMID: 34137045 DOI: 10.1002/hep.32019] [Reference Citation Analysis]
206 Kronsten VT, Tranah TH, Pariante C, Shawcross DL. Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol 2021:S0168-8278(21)02180-2. [PMID: 34800610 DOI: 10.1016/j.jhep.2021.11.008] [Reference Citation Analysis]
207 Holte K, Krag A, Gluud LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res 2012;42:1008-15. [PMID: 22548675 DOI: 10.1111/j.1872-034X.2012.01015.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 3.9] [Reference Citation Analysis]
208 D’amico G, Perricone G. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter? Curr Hepatology Rep 2019;18:144-56. [DOI: 10.1007/s11901-019-00473-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
209 Häussinger D, Butz M, Schnitzler A, Görg B. Pathomechanisms in hepatic encephalopathy. Biol Chem 2021;402:1087-102. [PMID: 34049427 DOI: 10.1515/hsz-2021-0168] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
210 Acharya C, Bajaj JS. Altered Microbiome in Patients With Cirrhosis and Complications. Clin Gastroenterol Hepatol 2019;17:307-21. [PMID: 30099098 DOI: 10.1016/j.cgh.2018.08.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
211 Kimer N, Krag A, Bendtsen F, Møller S, Gluud LL; Cochrane Hepato-Biliary Group. Rifaximin for people with hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd011585] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
212 Roberts SE, Button LA, Williams JG. Prognosis following upper gastrointestinal bleeding.PLoS One. 2012;7:e49507. [PMID: 23251344 DOI: 10.1371/journal.pone.0049507] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
213 Oey RC, Buck LEM, Erler NS, van Buuren HR, de Man RA. The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy. Therap Adv Gastroenterol 2019;12:1756284819858256. [PMID: 31258622 DOI: 10.1177/1756284819858256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
214 Bloom PP, Tapper EB. The Use of Administrative Data to Investigate the Population Burden of Hepatic Encephalopathy. J Clin Med 2020;9:E3620. [PMID: 33182743 DOI: 10.3390/jcm9113620] [Reference Citation Analysis]
215 Grønbæk L, Watson H, Vilstrup H, Jepsen P. Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites. United European Gastroenterol J 2018;6:407-12. [PMID: 29774154 DOI: 10.1177/2050640617727179] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
216 Sahlman P, Nissinen M, Pukkala E, Färkkilä M. Incidence, survival and cause-specific mortality in alcoholic liver disease: a population-based cohort study. Scandinavian Journal of Gastroenterology 2016;51:961-6. [DOI: 10.3109/00365521.2016.1157889] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
217 Julien J, Ayer T, Bethea ED, Tapper EB, Chhatwal J. Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study.Lancet Public Health. 2020;5:e316-e323. [PMID: 32504584 DOI: 10.1016/S2468-2667(20)30062-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
218 Gomez EV, Bertot LC, Rodriguez YS, Gonzalez AT, Perez YM, Garcia AY. The natural history of HCV-related cirrhosis and its temporal progression across the different clinical stages. Hepatol Int 2014;8:527-39. [DOI: 10.1007/s12072-014-9565-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
219 Asrani SK, Kamath PS. Natural history of cirrhosis. Curr Gastroenterol Rep. 2013;15:308. [PMID: 23314828 DOI: 10.1007/11894-0.12-0308-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
220 Shawcross DL. Diagnosis and management of hepatic encephalopathy. Br J Nurs 2018;27:S7-S13. [PMID: 29411990 DOI: 10.12968/bjon.2018.27.Sup3.S7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
221 Jiang D. Care of chronic liver disease. Prim Care 2011;38:483-98; viii-ix. [PMID: 21872093 DOI: 10.1016/j.pop.2011.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
222 Orman ES, Perkins A, Ghabril M, Khan BA, Chalasani N, Boustani MA. The confusion assessment method for the intensive care unit in patients with cirrhosis. Metab Brain Dis 2015;30:1063-71. [PMID: 25947193 DOI: 10.1007/s11011-015-9679-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
223 Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171. [PMID: 30266282 DOI: 10.1016/j.jhep.2018.09.014] [Cited by in Crossref: 615] [Cited by in F6Publishing: 559] [Article Influence: 153.8] [Reference Citation Analysis]
224 Tsai TY, Hung TH, Livneh H, Lin IH, Lu MC, Yeh CC. Chinese herbal medicine therapy and the risk of mortality for chronic hepatitis B patients with concurrent liver cirrhosis: a nationwide population-based cohort study. Oncotarget 2018;9:18214-23. [PMID: 29719600 DOI: 10.18632/oncotarget.24383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
225 Sheng JQ, Hu PJ, Liu X, Huang TS, Chen YH. Predictive Analytics for Care and Management of Patients With Acute Diseases: Deep Learning-Based Method to Predict Crucial Complication Phenotypes. J Med Internet Res 2021;23:e18372. [PMID: 33576744 DOI: 10.2196/18372] [Reference Citation Analysis]
226 Labenz C, Nagel M, Kremer WM, Hilscher M, Schilling CA, Toenges G, Kuchen R, Schattenberg JM, Galle PR, Wörns MA. Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis. Aliment Pharmacol Ther 2020;52:527-36. [PMID: 32598080 DOI: 10.1111/apt.15915] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
227 Shawcross DL. Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy? Expert Rev Gastroenterol Hepatol. 2015;9:539-542. [PMID: 25846450 DOI: 10.1586/17474124.2015.1035257] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
228 Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46:155-169. [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
229 Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113:175-194. [PMID: 29336434 DOI: 10.1038/ajg.2017.469] [Cited by in Crossref: 205] [Cited by in F6Publishing: 176] [Article Influence: 51.3] [Reference Citation Analysis]
230 Jepsen P, Vilstrup H, Lash TL. Development and validation of a comorbidity scoring system for patients with cirrhosis. Gastroenterology. 2014;146:147-156; quiz e15-e16. [PMID: 24055278 DOI: 10.1053/j.gastro.2013.09.019] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
231 Mikkelsen MR, Hendriksen C, Schiødt FV, Rydahl-hansen S. Alcoholic liver disease patients’ perspective of a coping and physical activity-oriented rehabilitation intervention after hepatic encephalopathy. J Clin Nurs 2016;25:2457-67. [DOI: 10.1111/jocn.13265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
232 Weissenborn K. Portosystemic encephalopathy. Neurologic Aspects of Systemic Disease Part II. Elsevier; 2014. pp. 661-74. [DOI: 10.1016/b978-0-7020-4087-0.00045-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
233 Saberifiroozi M. Improving Quality of Care in Patients with Liver Cirrhosis. Middle East J Dig Dis 2017;9:189-200. [PMID: 29255576 DOI: 10.15171/mejdd.2017.73] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
234 Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol 2014;109:1417-23. [PMID: 24935272 DOI: 10.1038/ajg.2014.154] [Cited by in Crossref: 125] [Cited by in F6Publishing: 108] [Article Influence: 15.6] [Reference Citation Analysis]
235 Huang YW, Yang SS, Kao JH. Pathogenesis and management of alcoholic liver cirrhosis: a review. Hepat Med 2011;3:1-11. [PMID: 24367215 DOI: 10.2147/HMER.S10265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
236 Lee JY, Cho Y, Hong MH, Kim J, Lee DH, Jung YJ, Kim BG, Lee KL, Kim W. Incidence, inhospital mortality, and readmission among patients with alcoholic hepatitis in Korea: A nationwide study. Journal of Gastroenterology and Hepatology 2019;34:747-54. [DOI: 10.1111/jgh.14513] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
237 Nguyen-khac E, Thiele M, Voican C, Nahon P, Moreno C, Boursier J, Mueller S, de Ledinghen V, Stärkel P, Gyune Kim S, Fernandez M, Madsen B, Naveau S, Krag A, Perlemuter G, Ziol M, Chatelain D, Diouf M. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. The Lancet Gastroenterology & Hepatology 2018;3:614-25. [DOI: 10.1016/s2468-1253(18)30124-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
238 Yin X, Zhang F, Xiao J, Wang Y, He Q, Zhu H, Leng X, Zou X, Zhang M, Zhuge Y. Diabetes mellitus increases the risk of hepatic encephalopathy after a transjugular intrahepatic portosystemic shunt in cirrhotic patients. Eur J Gastroenterol Hepatol. 2019;31:1264-1269. [PMID: 31136318 DOI: 10.1097/meg.0000000000001452] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
239 Haep N, Florentino RM, Squires JE, Bell A, Soto-Gutierrez A. The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone. Semin Liver Dis 2021;41:213-24. [PMID: 33992030 DOI: 10.1055/s-0041-1725023] [Reference Citation Analysis]